Table of Content

1 Key Insights

2 Executive Summary of Marginal Zone Lymphoma (MZL)

3 Marginal Zone Lymphoma (MZL) Market Overview at a Glance
3.1 Market Share (%) Distribution of MZL in 2017
3.2 Market Share (%) Distribution of MZL in 2030

4 Disease Background and Overview: Marginal Zone Lymphoma (MZL)
4.1 Introduction
4.2 Role of infectious etiologies in the pathogenesis of MZLB-cell lymphomas
4.2.1 Association of chronic inflammation and infectious agents with MZL at various anatomical sites
4.2.2 The H. pylori and gastric MALT lymphoma pathogenetic model
4.2.3 C. psittaci and ocular adnexal MZL
4.2.4 B. burgdorferi in cutaneous MZL
4.2.5 Immunoproliferative small intestinal disease and C. jejuni
4.2.6 A. xyloxidans and pulmonary MALT lymphoma
4.2.7 Hepatitis C virus and MZLs
4.3 Biology of marginal zone lymphoma
4.3.1 NF-_B signaling
4.3.2 NOTCH signaling
4.3.3 KLF2
4.3.4 PTPRD
4.3.5 Chromatin remodeling and epigenome regulation
4.3.6 Antigen stimulation
4.4 Diagnosis of MZL
4.4.1 MALT
4.4.2 Nodal MZL
4.4.3 Splenic MZL
4.5 ESMO Clinical Practice Guidelines for diagnosis of MZL
4.5.1 Staging and risk assessment

5 Case Reports
5.1 Preparatory intracranial dural marginal zone lymphoma: A Case Report
5.2 An extranodal marginal zone B-cell lymphoma involving superior rectus muscle: A clinicopathological case report
5.3 Primary spinal marginal zone lymphoma: Case report and review of the literature

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 KOL Views
6.3 Epidemiology Methodology
6.4 Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM
6.5 Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM

7 United States Epidemiology
7.1 Assumptions and Rationale
7.1.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States
7.1.2 Total incident cases of Marginal Zone Lymphoma (MZL) in the United States
7.1.3 Gender-specific incident cases of MZL in the United States
7.1.4 Subtype-specific incident cases of MZL in the United States
7.1.5 Stage-specific incident cases of MZL in the United States

8 EU5 Epidemiology
8.1 Assumptions and Rationale
8.2 Germany Epidemiology
8.2.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany
8.2.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Germany
8.2.3 Gender-specific incident cases of MZL in Germany
8.2.4 Subtype-specific incident cases of MZL in Germany
8.2.5 Stage-specific incident cases of MZL in Germany
8.3 France Epidemiology
8.3.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in France
8.3.2 Total incident cases of Marginal Zone Lymphoma (MZL) in France
8.3.3 Gender-specific incident cases of MZL in France
8.3.4 Subtype-specific incident cases of MZL in France
8.3.5 Stage-specific incident cases of MZL in France
8.4 Italy Epidemiology
8.4.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy
8.4.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Italy
8.4.3 Gender-specific incident cases of MZL in Italy
8.4.4 Subtype-specific incident cases of MZL in Italy
8.4.5 Stage-specific incident cases of MZL in Italy
8.5 Spain Epidemiology
8.5.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain
8.5.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Spain
8.5.3 Gender-specific incident cases of MZL in Spain
8.5.4 Subtype-specific incident cases of MZL in Spain
8.5.5 Stage-specific incident cases of MZL in Spain
8.6 United Kingdom Epidemiology
8.6.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in the United Kingdom
8.6.2 Total incident cases of Marginal Zone Lymphoma (MZL) in the UK
8.6.3 Gender-specific incident cases of MZL in the UK
8.6.4 Subtype-specific incident cases of MZL in the UK
8.6.5 Stage-specific incident cases of MZL in the UK

9 Japan Epidemiology
9.1 Assumptions and Rationale
9.1.1 Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan
9.1.2 Total incident cases of Marginal Zone Lymphoma (MZL) in Japan
9.1.3 Gender-specific incident cases of MZL in Japan
9.1.4 Subtype-specific incident cases of MZL in Japan
9.1.5 Stage-specific incident cases of MZL in Japan

10 Current Treatment and Medical Practices
10.1 EMZL
10.2 SMZL
10.3 Nodal MZL
10.4 Relapsing disease
10.5 ESMO recently published guidelines for diagnosis, treatment, and follow-up of MZL
10.6 Treatment Algorithm

11 Unmet needs

12 Marketed Drugs
12.1 Revlimid (lenalidomide) in combination with rituximab: Celgene Corporation, Bristol-Myers Squibb
12.1.1 Drug Description
12.1.2 Regulatory Milestones
12.1.3 Clinical Development
12.1.4 Safety and Efficacy
12.1.5 Product Profile
12.2 Imbruvica (ibrutinib): AbbVie, Janssen Biotech
12.2.1 Drug Description
12.2.2 Regulatory Milestones
12.2.3 Clinical Development
12.2.4 Safety and Efficacy
12.2.5 Product Profile

13 Emerging Drugs
13.1 Key Cross Competition
13.2 Umbralisib (TGR-1202): TG Therapeutics
13.2.1 Product Description
13.2.2 Other Developmental Activities
13.2.3 Clinical Development
13.2.4 Safety and Efficacy
13.2.5 Product Profile
13.3 Aliqopa (Copanlisib): Bayer
13.3.1 Product Description
13.3.2 Other Developmental Activities
13.3.3 Clinical Development
13.3.4 Safety and Efficacy
13.3.5 Product Profile
13.4 Ublituximab: TG Therapeutics
13.4.1 Product Description
13.4.2 Other Developmental Activities
13.4.3 Clinical Development
13.4.4 Safety and Efficacy
13.4.5 Product Profile
13.5 Obinutuzumab: Roche Pharma
13.5.1 Product Description
1.2.3 Other Developmental Activities
13.5.2 Clinical Development
13.5.3 Safety and Efficacy
13.5.4 Product Profile
13.6 Yescarta (axicabtagene ciloleucel): Gilead Sciences
13.6.1 Product Description
13.6.2 Other Developmental Activities
13.6.3 Clinical Development
13.6.4 Safety and Efficacy
13.6.5 Product Profile
13.7 Keytruda (Pembrolizumab): Merck Sharp & Dohme
13.7.1 Product Description
13.7.2 Other Developmental Activities
13.7.3 Clinical Development
13.7.4 Product Profile
13.8 CLR 131: Cellectar Biosciences
13.8.1 Product Description
13.8.2 Other Developmental Activities
13.8.3 Clinical Development
13.8.4 Safety and Efficacy
13.8.5 Product Profile
13.9 Parsaclisib: Innovent Biologics
13.9.1 Product Description
13.9.2 Other Developmental Activities
13.9.3 Clinical Development
13.9.4 Safety and Efficacy
13.9.5 Product Profile
13.1 Nivolumab (Oppdivo): Bristol-Myers Squibb
13.10.1 Product Description
13.10.2 Clinical Development
13.10.3 Safety and Efficacy
13.10.4 Product Profile
13.11 Calquence (acalabrutinib): Astrazeneca
13.11.1 Product Description
13.11.2 Clinical Development
13.11.3 Product Profile
13.12 Betalutin (177Lu-satetraxetan-lilotomab): Nordic Nanovector
13.12.1 Product Description
13.12.2 Other Developmental Activities
13.12.3 Clinical Development
13.12.4 Safety and Efficacy
13.12.5 Product Profile
13.13 Navitoclax (ABT-263): AbbVie
13.13.1 Product Description
13.13.2 Clinical Development
13.13.3 Safety and Efficacy
13.13.4 Product Profile
13.14 Orelabrutinib (ICP-022): InnoCare Pharma
13.14.1 Product Description
13.14.2 Other Developmental Activities
13.14.3 Clinical Development
13.14.4 Product Profile
13.15 M7583: Merck KGaA
13.15.1 Product Description
13.15.2 Other Developmental Activities
13.15.3 Clinical Development
13.15.4 Safety and Efficacy
13.15.5 Product Profile
13.16 ARQ 531: ArQule/Merck
13.16.1 Product Description
13.16.2 Other Developmental Activities
13.16.3 Clinical Development
13.16.4 Safety and Efficacy
13.16.5 Product Profile
13.17 Duvelisib: Verastem/Secura Bio
13.17.1 Product Description
13.17.2 Other Developmental Activities
13.17.3 Clinical Development
13.17.4 Safety and Efficacy
13.17.5 Product Profile
13.18 Zanubrutinib: BeiGene
13.18.1 Product Description
13.18.2 Other Developmental Activities
13.18.3 Clinical Development
13.18.4 Safety and Efficacy
13.18.5 Product Profile
13.19 Zandelisib: MEI Pharma
13.19.1 Product Description
13.19.2 Other Developmental Activities
13.19.3 Clinical Development
13.19.4 Safety and Efficacy
13.19.5 Product Profile
13.20 ALT-803: NantKwest/ImmunityBio
13.20.1 Product Description
13.20.2 Other Developmental Activities
13.20.3 Clinical Development
13.20.4 Safety and Efficacy
13.20.5 Product Profile
13.21 LOXO-305: Loxo Oncology/Eli Lilly
13.21.1 Product Description
13.21.2 Other Developmental Activities
13.21.3 Clinical Development
13.21.4 Safety and Efficacy
13.21.5 Product Profile
13.22 SD-101: TriSalus Life Sciences
13.22.1 Product Description
13.22.2 Other Developmental Activities
13.22.3 Clinical Development
13.22.4 Safety and Efficacy
13.22.5 Product Profile

14 Patient Journey

15 Marginal Zone Lymphoma (MZL): 7MM Analysis
15.1 Key Findings
15.2 Market Methodology
15.3 Market Size of Marginal Zone Lymphoma (MZL) in the 7MM
15.4 Market Size of Marginal Zone Lymphoma (MZL) by Line of Therapies in the 7MM
15.4.1 Market Size of Marginal Zone Lymphoma (MZL) by First-line therapies in the 7MM
15.4.2 Market Size of Marginal Zone Lymphoma (MZL) by Second-line therapies in the 7MM
15.4.3 Market Size of Marginal Zone Lymphoma (MZL) by Third-line therapies in the 7MM

16 Potential of Emerging Therapies

17 Key Market Forecast Assumptions

18 7MM Market Outlook

19 United States
19.1 United States Market Size
19.1.1 Total market size of Marginal Zone Lymphoma (MZL) in the United States
19.1.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of Therapies in the US

20 EU-5 Countries
20.1 Germany Market Size
20.1.1 Total Market size of Marginal Zone Lymphoma (MZL) in Germany
20.1.2 Market Size of Marginal Zone Lymphoma (MZL) by line of therapies in Germany
20.2 France Market Size
20.2.1 Total Market size of Marginal Zone Lymphoma (MZL) in France
20.2.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of therapies in France
20.3 Italy Market Size
20.3.1 Total Market size of Marginal Zone Lymphoma (MZL) in Italy
20.3.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of therapies in Italy
20.4 Spain Market Size
20.4.1 Total Market size of Marginal Zone Lymphoma (MZL) in Spain
20.4.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of therapies in Spain
20.5 United Kingdom Market Size
20.5.1 Total Market size of Marginal Zone Lymphoma (MZL) in the United Kingdom
20.5.2 Market Size of Marginal Zone Lymphoma (MZL) by Line of therapies in the UK

21 Japan
21.1 Japan Market Size
21.1.1 Total Market size of Marginal Zone Lymphoma (MZL) in Japan
21.1.2 Market Size of Marginal Zone Lymphoma (MZL) by line of therapies in Japan

22 Market Drivers

23 Market Barriers

24 SWOT Analysis

25 Reimbursement and Market access

26 Recognized Establishments

27 Appendix
27.1 Bibliography
27.2 Report Methodology

28 DelveInsight Capabilities

29 Disclaimer

30 About DelveInsight



List of Figures


Figure 1: H. pylori (HP)–induced lymphomagenesis
Figure 2: Summary of the main genetic and biologic features characterizing marginal zone lymphomas
Figure 3: Endoscopic Ultrasonography Staging of Gastric MALT Lymphoma
Figure 4: KOL Views
Figure 5: Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM (2017–2030)
Figure 6: Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM (2017–2030)
Figure 7: Global Heat Map of NHL
Figure 8: Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States (2017–2030)
Figure 9: Total incident cases of Marginal Zone Lymphoma (MZL) in the United States (2017–2030)
Figure 10: Gender-specific incident cases of MZL in the United States (2017–2030)
Figure 11: Subtype -specific incident cases of MZL in the United States (2017–2030)
Figure 12: Stage-specific incident cases of MZL in the United States (2017–2030)
Figure 13: Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany (2017–2030)
Figure 14: Total incident cases of Marginal Zone Lymphoma (MZL) in Germany (2017–2030)
Figure 15: Gender-specific incident cases of MZL in Germany (2017–2030)
Figure 16: Subtype-specific incident cases of MZL in Germany (2017–2030)
Figure 17: Stage-specific incident cases of MZL in Germany (2017–2030)
Figure 18: Total incident cases of Non-Hodgkin lymphoma (NHL) in France (2017–2030)
Figure 19: Total incident cases of Marginal Zone Lymphoma (MZL) in France (2017–2030)
Figure 20: Gender-specific incident cases of MZL in France (2017–2030)
Figure 21: Subtype-specific incident cases of MZL in France (2017–2030)
Figure 22: Stage-specific incident cases of MZL in France (2017–2030)
Figure 23: Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy (2017–2030)
Figure 24: Total incident cases of Marginal Zone Lymphoma (MZL) in Italy (2017–2030)
Figure 25: Gender-specific incident cases of MZL in Italy (2017–2030)
Figure 26: Subtype-specific incident cases of MZL in Italy (2017–2030)
Figure 27: Stage-specific incident cases of MZL in Italy (2017–2030)
Figure 28: Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain (2017–2030)
Figure 29: Total incident cases of Marginal Zone Lymphoma (MZL) in Spain (2017–2030)
Figure 30: Gender-specific incident cases of MZL in Spain (2017–2030)
Figure 31: Subtype-specific incident cases of MZL in Spain (2017–2030)
Figure 32: Stage-specific incident cases of MZL in Spain (2017–2030)
Figure 33: Total incident cases of Non-Hodgkin lymphoma (NHL) in the UK (2017–2030)
Figure 34: Total incident cases of Marginal Zone Lymphoma (MZL) in the UK (2017–2030)
Figure 35: Gender-specific incident cases of MZL in the UK (2017–2030)
Figure 36: Subtype-specific incident cases of MZL in the UK (2017–2030)
Figure 37: Stage-specific incident cases of MZL in the UK (2017–2030)
Figure 38: Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan (2017–2030)
Figure 39: Total incident cases of Marginal Zone Lymphoma (MZL) in Japan (2017–2030)
Figure 40: Gender-specific incident cases of MZL in Japan (2017–2030)
Figure 41: Subtype-specific incident cases of MZL in Japan (2017–2030)
Figure 42: Stage-specific incident cases of MZL in Japan (2017–2030)
Figure 43: Classification of MZL
Figure 44: Treatment algorithm for localized gastric MZL
Figure 45: Treatment algorithms for advanced gastric MZL and non-gastric EMZ
Figure 46: Treatment algorithm for gastric MALT lymphoma
Figure 47: Treatment of splenic MZL
Figure 48: Treatment of Non-gastric MALT Lymphoma
Figure 49: Gastric MALT Lymphoma
Figure 50: Splenic MZL
Figure 51: Non-gastric MALT Lymphoma
Figure 52: Unmet needs
Figure 53: Market Size of Marginal Zone Lymphoma (MZL) in the 7MM in USD Million (2017–2030)
Figure 54: Market Size of MZL by First-line therapies in the 7MM, in USD Million (2017–2030)
Figure 55: Market Size of MZL by Second-line therapies in the 7MM, in USD Million (2017–2030)
Figure 56: Market Size of MZL by Third-line therapies in the 7MM, in USD Million (2017–2030)
Figure 57: Market Size of Marginal Zone Lymphoma (MZL) in the US, USD Millions (2017–2030)
Figure 58: Market Size of MZL by First-line Therapies in the US, in USD Million (2017–2030)
Figure 59: Market Size of MZL by Second-line Therapies in the US, in USD Million (2017–2030)
Figure 60: Market Size of MZL by Third-line Therapies in the US, in USD Million (2017–2030)
Figure 61: Market Size of Marginal Zone Lymphoma (MZL) in Germany, USD Millions (2017–2030)
Figure 62: Market Size of MZL by First-line Therapies in Germany, in USD Million (2017–2030)
Figure 63: Market Size of MZL by Second-line Therapies in Germany, in USD Million (2017–2030)
Figure 64: Market Size of MZL by Third-line Therapies in Germany, in USD Million (2017–2030)
Figure 65: Market Size of Marginal Zone Lymphoma (MZL) in France, USD Millions (2017–2030)
Figure 66: Market Size of MZL by First-line Therapies in France, in USD Million (2017–2030)
Figure 67: Market Size of MZL by Second-line Therapies in France, in USD Million (2017–2030)
Figure 68: Market Size of MZL by Third-line Therapies in France, in USD Million (2017–2030)
Figure 69: Market Size of Marginal Zone Lymphoma (MZL) in Italy, USD Millions (2017–2030)
Figure 70: Market Size of MZL by First-line Therapies in Italy, in USD Million (2017–2030)
Figure 71: Market Size of MZL by Second-line Therapies in Italy, in USD Million (2017–2030)
Figure 72: Market Size of MZL by Third-line Therapies in Italy, in USD Million (2017–2030)
Figure 73: Market Size of Marginal Zone Lymphoma (MZL) in Spain, USD Millions (2017–2030)
Figure 74: Market Size of MZL by First-line Therapies in Spain, in USD Million (2017–2030)
Figure 75: Market Size of MZL by Second-line Therapies in Spain, in USD Million (2017–2030)
Figure 76: Market Size of MZL by Third-line Therapies in Spain, in USD Million (2017–2030)
Figure 77: Market Size of Marginal Zone Lymphoma (MZL) in the UK, USD Millions (2017–2030)
Figure 78: Market Size of MZL by First-line Therapies in the UK, in USD Million (2017–2030)
Figure 79: Market Size of MZL by Second-line Therapies in in the UK, in USD Million (2017–2030)
Figure 80: Market Size of MZL by Third-line Therapies in the UK, in USD Million (2017–2030)
Figure 81: Market Size of Marginal Zone Lymphoma (MZL) in Japan, USD Millions (2017–2030)
Figure 82: Market Size of MZL by First-line Therapies in Japan, in USD Million (2017–2030)
Figure 83: Market Size of MZL by Second-line Therapies in Japan, in USD Million (2017–2030)
Figure 84: Market Size of MZL by Third-line Therapies in Japan, in USD Million (2017–2030)
Figure 85: Market Drivers
Figure 86: Market Barriers
Figure 87: SWOT Analysis of Marginal Zone Lymphoma (MZL)


List of Tables


Table 1: Summary of Marginal Zone Lymphoma (MZL), Market, Epidemiology and Key Events (2017–2030)
Table 2: Total Incident Cases of Non-Hodgkin lymphoma (NHL) in the 7MM (2017–2030)
Table 3: Total Incident Cases of Marginal Zone Lymphoma (MZL) in the 7MM (2017–2030)
Table 4: Major Sources Used
Table 5: Total incident cases of Non-Hodgkin lymphoma (NHL) in the United States (2017–2030)
Table 6: Total incident cases of Marginal Zone Lymphoma (MZL) in the United States (2017–2030)
Table 7: Gender-specific incident cases of MZL in the United States (2017–2030)
Table 8: Subtype-specific incident cases of MZL in the United States (2017–2030)
Table 9: Stage-specific incident cases of MZL in the United States (2017–2030)
Table 10: Total incident cases of Non-Hodgkin lymphoma (NHL) in Germany (2017–2030)
Table 11: Total incident cases of Marginal Zone Lymphoma (MZL) in Germany (2017–2030)
Table 12: Gender-specific incident cases of MZL in Germany (2017–2030)
Table 13: Subtype-specific incident cases of MZL in Germany (2017–2030)
Table 14: Stage-specific incident cases of MZL in Germany (2017–2030)
Table 15: Total incident cases of Non-Hodgkin lymphoma (NHL) in France (2017–2030)
Table 16: Total incident cases of Marginal Zone Lymphoma (MZL) in France (2017–2030)
Table 17: Gender-specific incident cases of MZL in France (2017–2030)
Table 18: Subtype-specific incident cases of MZL in France (2017–2030)
Table 19: Stage-specific incident cases of MZL in France (2017–2030)
Table 20: Total incident cases of Non-Hodgkin lymphoma (NHL) in Italy (2017–2030)
Table 21: Total incident cases of Marginal Zone Lymphoma (MZL) in Italy(2017–2030)
Table 22: Gender-specific incident cases of MZL in Italy (2017–2030)
Table 23: Type-specific incident cases of MZL in Italy (2017–2030)
Table 24: Stage-specific incident cases of MZL in Italy (2017–2030)
Table 25: Total incident cases of Non-Hodgkin lymphoma (NHL) in Spain (2017–2030)
Table 26: Total incident cases of Marginal Zone Lymphoma (MZL) in Spain (2017–2030)
Table 27: Gender-specific incident cases of MZL in Spain (2017–2030)
Table 28: Subtype-specific incident cases of MZL in Spain (2017–2030)
Table 29: Stage-specific incident cases of MZL in Spain (2017–2030)
Table 30: Total incident cases of Non-Hodgkin lymphoma (NHL) in the UK (2017–2030)
Table 31: Total incident cases of Marginal Zone Lymphoma (MZL) in the UK (2017–2030)
Table 32: Gender-specific incident cases of MZL in the UK (2017–2030)
Table 33: Subtype-specific incident cases of MZL in the UK (2017–2030)
Table 34: Stage-specific incident cases of MZL in the UK (2017–2030)
Table 35: Total incident cases of Non-Hodgkin lymphoma (NHL) in Japan (2017–2030)
Table 36: Total incident cases of Marginal Zone Lymphoma (MZL) in Japan(2017–2030)
Table 37: Gender-specific incident cases of MZL in Japan (2017–2030)
Table 38: Subtype-specific incident cases of MZL in Japan (2017–2030)
Table 39: Stage-specific incident cases of MZL in Japan (2017–2030)
Table 40: Rituximab Plus Lenalidomide, Clinical Trial Description, 2020
Table 41: Imbruvica (ibrutinib), Clinical Trial Description, 2020
Table 42: Comparison of emerging drugs under development
Table 43: Comparison of emerging drugs under early phase of development for MZL
Table 44: Umbralisib, Clinical Trial Description, 2020
Table 45: Aliqopa (Copanlisib), Clinical Trial Description, 2020
Table 46: Ublituximab, Clinical Trial Description, 2020
Table 47: Obinutuzumab Clinical Trial Description, 2020
Table 48: Yescarta (axicabtagene ciloleucel), Clinical Trial Description, 2020
Table 49: Keytruda (Pembrolizumab), Clinical Trial Description, 2020
Table 50: CLR 131, Clinical Trial Description, 2020
Table 51: Parsaclisib, Clinical Trial Description, 2020
Table 52: Nivolumab, Clinical Trial Description, 2020
Table 53: Calquence, Clinical Trial Description, 2020
Table 54: Betalutin, Clinical Trial Description, 2020
Table 55: ABT-263, Clinical Trial Description, 2020
Table 56: ICP-022, Clinical Trial Description, 2020
Table 57: M7583, Clinical Trial Description, 2020
Table 58: ARQ 531, Clinical Trial Description, 2020
Table 59: Duvelisib, Clinical Trial Description, 2020
Table 60: Zanubrutinib, Clinical Trial Description, 2020
Table 61: Zandelisib, Clinical Trial Description, 2020
Table 62: ALT-803, Clinical Trial Description, 2020
Table 63: LOXO-305, Clinical Trial Description, 2020
Table 64: SD-101, Clinical Trial Description, 2020
Table 65: Market Size of Marginal Zone Lymphoma (MZL) in the 7MM in USD Million (2017–2030)
Table 66: Market Size of MZL by First-line therapies in the 7MM, in USD Million (2017–2030)
Table 67: Market Size of MZL by Second-line therapies in the 7MM, in USD Million (2017–2030)
Table 68: Market Size of MZL by Third-line therapies in the 7MM, in USD Million (2017–2030)
Table 69: Key market forecast assumptions for Umbralisib (TGR-1202)
Table 70: Key market forecast assumptions for Duvelisib
Table 71: Key market forecast assumptions for Ublituximab
Table 72: Key market forecast assumptions for Aliqopa (copanlisib)
Table 73: Key market forecast assumptions for Calquence (Acalabrutinib)
Table 74: Key market forecast assumptions for Zanubrutinib (BGB-3111)
Table 75: Key market forecast assumptions for Zandelisib (ME-401)
Table 76: Key market forecast assumptions for Parsaclisib (IBI-376)
Table 77: Key market forecast assumptions for Yescarta (axicabtagene ciloleucel)
Table 78: Key market forecast assumptions for Betalutin
Table 79: Key market forecast assumptions for CLR 131
Table 80: The US Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017–2030)
Table 81: Market Size of MZL by First-line therapies in the US, in USD Million (2017–2030)
Table 82: Market Size of MZL by Second-line therapies in the US, in USD Million (2017–2030)
Table 83: Market Size of MZL by Third-line therapies in the US, in USD Million (2017–2030)
Table 84: Germany Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017–2030)
Table 85: Market Size of MZL by First-line therapies in Germany, in USD Million (2017–2030)
Table 86: Market Size of MZL by Second-line therapies in Germany, in USD Million (2017–2030)
Table 87: Market Size of MZL by Third-line therapies in Germany, in USD Million (2017–2030)
Table 88: France Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017–2030)
Table 89: Market Size of MZL by First-line therapies in France, in USD Million (2017–2030)
Table 90: Market Size of MZL by Second-line therapies in France, in USD Million (2017–2030)
Table 91: Market Size of MZL by Third-line therapies in France, in USD Million (2017–2030)
Table 92: Italy Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017–2030)
Table 93: Market Size of MZL by First-line therapies in Italy, in USD Million (2017–2030)
Table 94: Market Size of MZL by Second-line therapies in Italy, in USD Million (2017–2030)
Table 95: Market Size of MZL by Third-line therapies in Italy, in USD Million (2017–2030)
Table 96: Spain Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017–2030)
Table 97: Market Size of MZL by First-line therapies in Spain, in USD Million (2017–2030)
Table 98: Market Size of MZL by Second-line therapies in Spain, in USD Million (2017–2030)
Table 99: Market Size of MZL by Third-line therapies in Spain, in USD Million (2017–2030)
Table 100: The UK Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017–2030)
Table 101: Market Size of MZL by First-line therapies in the UK, in USD Million (2017–2030)
Table 102: Market Size of MZL by Second-line therapies in the UK, in USD Million (2017–2030)
Table 103: Market Size of MZL by Third-line therapies in the UK, in USD Million (2017–2030)
Table 104: Japan Market Size of Marginal Zone Lymphoma (MZL) in USD Million (2017–2030)
Table 105: Market Size of MZL by First-line therapies in Japan, in USD Million (2017–2030)
Table 106: Market Size of MZL by Second-line therapies in Japan, in USD Million (2017–2030)
Table 107: Market Size of MZL by Third-line therapies in Japan, in USD Million (2017–2030)